Chairman Cassidy: Please Ask Dr. Overton About FDA Decision-Making
With Dr. Heidi Overton’s FDA Commissioner nomination pending, the Senate HELP Committee faces a choice bigger than any single policy flashpoint. Beyond questions on vaccines, mifepristone, or the MAHA agenda, the real test is whether Overton will restore science-based, transparent decision-making after a predecessor who made fiat-like calls while claiming “gold standard science” and “radical transparency.” The FDA’s global credibility — and its promise of “no surprises” — hangs on getting this right.
FDA Matters provides short-form analysis of FDA policy and regulatory issues. We know you are busy, so we publish 1 to 2 columns per week, each a 3-5 minute read.
FDA Matters does not report the news….we provide analysis of what’s behind the news.
FDA Matters advocates for a more effective, efficient, and fair FDA.
FDA Matters has been featured in:
The FDA’s Century-Long Campaign to Assure Safe Manufacturing (Part 2)
A Larger Context for Readers Monitoring FDA’s Review of Unapproved Peptide Drugs For more than a century, FDA has been working towards ensuring that drugs are consistently manufactured at scale to FDA standards. As a result, consumers can be largely assured of drugs…
The FDA’s Century-Long Campaign to Assure Safe Drug Manufacturing (Part 1)
Initial FDA approval gets all the glory in the world of drugs and biologics. However, that approval has limited value if patients cannot rely upon receiving the original FDA-approved drug product (or an FDA-approved generic or biosimilar). For over one hundred years,…
A Marathon, Not a Sprint: The Long Road to Becoming the Next FDA Commissioner
Around DC, there are a lot of smart people talking about the race to fill the job of FDA Commissioner. To me, it’s more of a slog than a race; certainly, more of a marathon than a sprint. It’s highly unlikely that anyone will be nominated soon, and no one will be…
Firing Dr. Makary Solves No Problems….BUT Opens the Door for More Orderly Management and Decision-Making
Drew Armstrong at Endpoints News brilliantly titled his summary of the Makary era: “An Impossible Job, Done Badly.” (here) I could not agree more. Unfortunately, nothing about the “impossible job” of FDA leadership has been made any easier or better by Dr. Makary’s…
Spotlight: The Partnership for Safe Medicines (PSM)
Dear FDA Matters readers: FDA Matters’ newest feature puts a spotlight on causes and organizations that affect FDA and the FDA stakeholder community. Two prior Spotlight columns are here and here. More will follow. If you are aware of a cause or an organization that…
Compounding, Patient Safety, and the Vital Role of FDA Enforcement
Over the last two years, few FDA topics have consumed more sustained attention than the mass compounding of commercially available drugs. GLP-1 (glucagon-like peptide-1 receptor agonists) drugs have been the focus of most of the public discussion. However, our…